Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
89bio, Inc. (ETNB)  
$10.16 0.06 (0.59%) as of 4:30 Thu 7/3


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 161,930,000
Market Cap: 1.65(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $4.83 - $11.66
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 24.2
Insider 3/6 Months : 24.8
Guru Rank Number :  733
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 5,729,285 5,754,285 7,104,285
Total Buy Value $0 $50,099,844 $50,302,794 $71,025,294
Total People Bought 0 2 3 3
Total Buy Transactions 0 3 6 7
Total Shares Sold 15,329 26,292 54,247 173,942
Total Sell Value $91,208 $162,358 $389,353 $1,807,679
Total People Sold 1 1 1 3
Total Sell Transactions 1 2 3 7
End Date 2025-04-06 2025-01-03 2024-07-05 2023-07-06

   
Records found: 89
  Page 1 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Hayden Michael R   –       •      –    2023-03-28 4 B $16.15 $993,839 I/I 61,538 61,538 0.01 -5%     
   Shah Rajeev M. Director   –       •       •   2023-03-24 4 B $16.25 $39,999,993 I/I 2,461,538 11,081,584 2.25 -1%     
   Martins Ryan Chief Financial Officer   •       –      –    2023-03-23 4 AS $16.11 $80,550 D/D (5,000) 53,578 -8%     
   Palekar Rohan Chief Executive Officer   •       •      –    2023-03-23 4 AS $16.00 $240,000 D/D (15,000) 269,080 -8%     
   Atkinson Edward Morrow Iii Director   –       •      –    2023-03-01 4 AS $13.60 $136,000 D/D (10,000) 0 35%     
   Atkinson Edward Morrow Iii Director   –       •      –    2023-03-01 4 OE $4.44 $44,400 D/D 10,000 10,000     -
   Martins Ryan Chief Financial Officer   •       –      –    2023-02-21 4 AS $13.89 $35,281 D/D (2,540) 58,578 36%     
   Le-Nguyen Quoc See Remarks   •       –      –    2023-02-17 4 D $13.97 $29,896 D/D (2,140) 91,179     -
   Martins Ryan Chief Financial Officer   •       –      –    2023-02-17 4 D $13.97 $24,448 D/D (1,750) 61,118     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2023-02-17 4 D $13.97 $29,714 D/D (2,127) 94,671     -
   Palekar Rohan Chief Executive Officer   •       •      –    2023-02-17 4 D $13.97 $87,718 D/D (6,279) 284,072     -
   Le-Nguyen Quoc See Remarks   •       –      –    2023-02-09 4 A $0.00 $0 D/D 30,000 93,319     -
   Martins Ryan Chief Financial Officer   •       –      –    2023-02-09 4 A $0.00 $0 D/D 30,000 62,868     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2023-02-09 4 A $0.00 $0 D/D 30,000 96,798     -
   Palekar Rohan Chief Executive Officer   •       •      –    2023-02-09 4 A $0.00 $0 D/D 75,000 290,351     -
   Martins Ryan Chief Financial Officer   •       –      –    2023-02-08 4 AS $14.41 $21,327 D/D (1,480) 32,868 36%     
   Martins Ryan Chief Financial Officer   •       –      –    2023-02-05 4 D $13.24 $7,838 D/D (592) 34,348     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2023-02-05 4 D $13.24 $18,006 D/D (1,360) 66,798     -
   Palekar Rohan Chief Executive Officer   •       •      –    2023-02-05 4 D $13.24 $53,993 D/D (4,078) 215,351     -
   Le-Nguyen Quoc See Remarks   •       –      –    2023-02-05 4 D $13.24 $18,404 D/D (1,390) 63,319     -
   Martins Ryan Chief Financial Officer   •       –      –    2023-02-03 4 AS $12.70 $46,848 D/D (3,592) 35,368 62%     
   Martins Ryan Chief Financial Officer   •       –      –    2023-02-03 4 OE $3.11 $9,330 D/D 3,000 38,960     -
   Le-Nguyen Quoc See Remarks   •       –      –    2023-02-01 4 D $12.05 $8,375 D/D (695) 64,709     -
   Martins Ryan Chief Financial Officer   •       –      –    2023-02-01 4 D $12.05 $4,916 D/D (408) 35,960     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2023-02-01 4 D $12.05 $8,194 D/D (680) 68,158     -
  89 Records found
  1  2  3  4   
  Page 1 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us